Royalty Pharma

RPRX · NASDAQ

$62.25+$1.98 (+3.29%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $60.27

Latest news

Press releaseSep 15, 4:35 PM ETGlobe Newswire
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NewsSep 8, 10:19 AM ETKaustubh Bagalkote
Why Is Eli Lilly Stock Falling Tuesday?
NewsSep 8, 8:01 AM ETVandana Singh
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
NewsAug 13, 1:07 PM ETVandana Singh
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Press releaseAug 12, 4:10 PM ETGlobe Newswire
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Press releaseAug 12, 4:05 PM ETGlobe Newswire
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
NewsAug 5, 7:27 AM ET
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Press releaseAug 5, 7:00 AM ETGlobe Newswire
Royalty Pharma reports second quarter 2026 results
NewsAug 3, 8:01 AM ETAvi Kapoor
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Press releaseJul 22, 7:05 AM ETGlobe Newswire
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
NewsJul 22, 6:54 AM ET
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront
NewsJul 7, 2:21 PM ETVandana Singh
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
NewsJun 29, 9:20 AM ETVandana Singh
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
NewsMay 6, 9:56 AM ET
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
NewsMay 6, 7:24 AM ET
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate
Press releaseMay 6, 7:00 AM ETGlobe Newswire
Royalty Pharma reports first quarter 2026 results
NewsFeb 11, 7:06 AM ET
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
Press releaseFeb 11, 7:00 AM ETGlobe Newswire
Royalty Pharma Reports Q4 and Full Year 2025 Results
Press releaseJan 12, 7:15 AM ETGlobe Newswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
NewsJan 9, 1:52 AM ETVishaal Sanjay
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
NewsDec 31, 10:47 AM ETVandana Singh
What's Going On With Royalty Pharma Stock Wednesday?
Press releaseDec 12, 10:47 AM ETPRNewswire
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
NewsDec 5, 11:49 AM ETVandana Singh
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
NewsNov 5, 1:23 PM ETPiero Cingari
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Press releaseNov 5, 7:00 AM ETGlobe Newswire
Royalty Pharma Reports Third Quarter 2025 Results
Press releaseSep 11, 7:00 AM ETGlobe Newswire
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
NewsAug 25, 1:19 PM ETVandana Singh
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Press releaseAug 25, 6:00 AM ETBusiness Wire
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Royalty Pharma Reports Second Quarter 2025 Results
NewsJun 23, 11:00 AM ET
A Look Into Royalty Pharma Inc's Price Over Earnings
Press releaseMay 12, 4:15 PM ETGlobe Newswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseApr 24, 8:30 AM ETBusiness Wire
U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)
Press releaseFeb 11, 7:15 AM ETGlobe Newswire
Royalty Pharma Reports Q4 and Full Year 2024 Results
NewsJan 22, 3:43 PM ETVandana Singh
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Press releaseJan 10, 7:30 AM ETGlobe Newswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Press releaseNov 27, 4:15 PM ETGlobe Newswire
Royalty Pharma to Present at Upcoming Investor Conferences
NewsNov 6, 8:39 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
NewsNov 5, 9:02 AM ET
Insights Ahead: Royalty Pharma's Quarterly Earnings
Press releaseNov 4, 4:01 PM ETPRNewswire
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
NewsSep 18, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
NewsSep 4, 9:09 AM ETVandana Singh
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program

Why Is Eli Lilly Stock Falling Tuesday?

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma reports second quarter 2026 results

AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Earnings Scheduled For May 6, 2026

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Royalty Pharma reports first quarter 2026 results

Royalty Pharma Q4 Earnings Report: What Investors Need to Know

Royalty Pharma Reports Q4 and Full Year 2025 Results

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

What's Going On With Royalty Pharma Stock Wednesday?

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Royalty Pharma Reports Third Quarter 2025 Results

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Royalty Pharma Reports Second Quarter 2025 Results

A Look Into Royalty Pharma Inc's Price Over Earnings

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

Earnings Scheduled For May 8, 2025

U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

Royalty Pharma Reports Q4 and Full Year 2024 Results

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Royalty Pharma to Present at Upcoming Investor Conferences

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Insights Ahead: Royalty Pharma's Quarterly Earnings

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

10 Health Care Stocks With Whale Alerts In Today's Session

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut